|
Supriya Lifescience Ltd posted results for Q1 FY27. The company witnessed a 30.8% year-over-year growth in revenue to Rs. 189.75 crore compared to Rs. 145.07 crore in Q1 FY26.
EBITDA for Q1 FY27 stood at Rs. 47.46 crore, with an EBITDA margin of 25.0%, as against Rs. 51.70 crore in Q1 FY26 with a margin of 35.6%. The profit after tax (PAT) for Q1 FY27 was Rs. 24.04 crore, compared to Rs. 34.79 crore in Q1 FY26. The PAT margin stood at 12.7% in Q1 FY27 versus 24.0% in Q1 FY26.
The anaesthetic segment continued to be the largest therapeutic contributor in Q1 FY27, accounting for 48% of revenue, compared to 53% in Q1 FY26. Vitamins contributed 17% of revenue in Q1 FY27, compared to 11% in Q1 FY26.Export contribution stood at 81% of Q1 FY27 revenue, reflecting the company’s continued focus on global markets and diversified geographic presence.
The company continues to strengthen its R&D capabilities, with 68+ scientists focused primarily on API and formulation process development. The company has also started two R&D centres at Ambernath and Lote, while continuing efforts to add 3–4 products annually.
Dr Satish Wagh, executive chairman and whole-time director, Supriya Lifescience Ltd., commenting on the results, said, “Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets. Our focus remains on expanding our product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments. With a strong export-oriented business, continued investments in capacity and innovation, and a growing pipeline across anaesthetic and ADHD, we remain focused on building sustainable long-term growth.”
|